FastEnzymes
CLINICAL STUDIES ON THE FOLLOWING INGREDIENTS:
Digestive Enzymes (Protease, Amylase, Lactase, Lipase, & Cellulase)
Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal
Abstract
In a double-blind, crossover study, we determined whether microencapusulated pancreatic enzymes reduce postprandial symptoms experienced by healthy volunteers after ingestion of a high calorie, high fat meal. At 7 AM, 18 subjects ingested 185 g of cookies (1196 calories and 72 g of fat) with three pancrelipase capsules or a placebo. The severity of gastrointestinal symptoms and flatus passages were recorded for 15-17 hr, and end-alveolar samples were obtained hourly for 10 hr. Ingestion of pancreatic supplements was associated with a significant (P = 0.049) reduction in bloating over the entire recording period, and with significant reductions in bloating, gas, and fullness during the dinner to bedtime period. Pancreatic supplements had no significant effect on breath H2 or CH4 concentration. The finding that pancreatic supplements reduce postprandial symptoms in healthy subjects suggests that these supplements also might be beneficial in irritable bowel syndrome.
Source: Suarez F, Levitt MD, Adshead J, Barkin JS. “Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal.” Dig Dis Sci. (1999);44(7):1317-21.
The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial
Abstract
Background: Lactase enzyme supplements and probiotics with high beta-galactosidase activity may be valid treatment options for the lactose intolerance. Aim of this study was to assess whether supplementation with tilactase or Lactobacillus reuteri when compared to placebo affects hydrogen breath excretion and gastrointestinal symptoms in lactose intolerant patients during lactose breath test (H,-LBT).
Methods: Sixty lactose intolerant patients participated in the study and were randomized to three 20 patients-treatment groups: tilactase group (tilactase 15 minutes before control H2-LBT); placebo group (placebo 15 minutes before control H2-LBT); Lactobacillus reuteri group (LR) (LR b.i.d. during 10 days before control H2-LBT). The outcomes were LBT normalization rate, and influences of treatments on both mean maximum hydrogen concentration and clinical score.
Results: LBT normalization rate was significantly higher in tilactase and LR groups with respect to placebo. Tilactase was significantly more effective than LR in achieving LBT normalization (p < 0.01). Both significant reduction of mean peak H2 excretion and improvement of the mean clinical score were observed in tilactase and LR groups after treatment with respect to placebo (p < 0.0001). Tilactase was significantly more effective than LR in reducing both mean peak hydrogen excretion and mean clinical score.
Conclusions: In lactose intolerants, tilactase strongly improves both LBT results and gastrointestinal symptoms after lactose ingestion with respect to placebo. Lactobacillus reuteri also is effective but lesser than tilactase. This probiotic may represent an interesting treatment option for lactose intolerance since its use is simple and its effect may last in the time after stopping administration.
Source: Ojetti V, Gigante G, Gabrielli M, Ainora ME, Mannocci A, Lauritano EC, Gasbarrini G, Gasbarrini A. “The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial.” Eur Rev Med Pharmacol Sci. (2010);14(3):163-70.
The efficacy of Combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo-controlled and cross-over study: Shanghai Combizym Clinical Cooperative Group
Abstract
Objective: To evaluate the efficacy and safety of Combizym treatment in Chinese patients with dyspepsia.
Methods: In this multicenter, randomized, placebo-controlled cross-over study, a total of 151 patients (76 men and 75 women, mean age: 44.67 +/- 6.46 years, range: 22-67 years) with dyspepsia whose symptoms were not relieved by placebos were recruited. They were randomly divided into group A (79 patients, 2 weeks of Combizym treatment, two tablets post-meal, t.i.d.; then 1 week of wash-out, followed by 2 weeks of placebo treatment, two tablets post-meal, t.i.d.) or group B (72 patients, 2 weeks of placebo treatment, two tablets post-meal, t.i.d. then one week of wash-out, followed by 2 weeks of Combizym treatment, 2 tablets post-meal, t.i.d.). The index of severity of the dyspepsia symptoms was evaluated before and after each treatment phase with Combizym or the placebo.
Results: Compared with the placebo, 2 weeks of Combizym treatment decreased the severity index of dyspepsia symptoms significantly (27.64 +/- 1.77 to 9.72 +/- 1.33 vs 23.99 +/- 1.28 to 22.03 +/- 1.40, P < 0.01). The efficacy rates of Combizym and the placebo on dyspepsia were 89.63% and 21.68%, respectively (P < 0.01). According to the improvement of symptoms index, individual dyspepsia symptoms that could be attenuated by Combizym therapy were anepithymia, abdominal distension, belching, diarrhea, abdominal pain, epigastric burning. None of patients reported adverse events during the study.
Conclusion: Combizym treatment effectively ameliorates dyspepsia symptoms in Chinese patients, with satisfactory safety and compliance.
Source: Ran ZH, Yuan YZ, Li ZS, Wang JY, Zong CH, Xie WF, Zheng P, Chen SL, Zhan XB, Chen SY, Xiao SD. “The efficacy of Combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo-controlled and cross-over study: Shanghai Combizym Clinical Cooperative Group.” J Dig Dis. *2009);10(1):41-8.
[Effect of dietary supplements with different cellulose content on the blood glucose and insulin levels in type II diabetes mellitus]
Abstract
The influence of cellulose-containing vegetables, added to the breakfast, on the blood glucose and insulin levels, was investigated in patients, suffering from type II diabetes mellitus and healthy humans. It was shown, that cellulose promotes a decrease in the glycemia and a rise in the insulin level 1 to 1.5 hours after the breakfast. On the basis of their own results and data of other authors it was concluded that cellulose exerts a good effect upon the blood glucose level and its use should be recommended as a dietetic treatment component in patients with type II diabetes mellitus.
Source: Korotkova VD, Perelygina AA, Lobanova AM, Stoilov LD. Vliianie pishchevykh nagruzok s razlichnym soderzhaniem kletchatki na uroven' gliukozy i insulina v krovi u bol'nykh sakharnym diabetom II tipa “[Effect of dietary supplements with different cellulose content on the blood glucose and insulin levels in type II diabetes mellitus].” Probl Endokrinol (Mosk). (1983);29(6):16-9.
Digestive Enzyme Supplementation in Gastrointestinal Diseases
Abstract
Background: Digestive enzymes are able to break down proteins and carbohydrates and lipids, and their supplementation may play a role in the management of digestive disorders, from lactose intolerance to cystic fibrosis. To date, several formulations of digestive enzymes are available on the market, being different each other in terms of enzyme type, source and origin, and dosage.
Methods: This review, performed through a non-systematic search of the available literature, will provide an overview of the current knowledge of digestive enzyme supplementation in gastrointestinal disorders, discussion of the use of pancreatic enzymes, lactase (β-galactosidase) and conjugated bile acids, and also exploring the future perspective of digestive enzyme supplementation.
Results: Currently, the animal-derived enzymes represent an established standard of care, however the growing study of plant-based and microbe-derived enzymes offers great promise in the advancement of digestive enzyme therapy.
Conclusion: New frontiers of enzyme replacement are being evaluated also in the treatment of diseases not specifically related to enzyme deficiency, whereas the combination of different enzymes might constitute an intriguing therapeutic option in the future.
Source: Ianiro G, Pecere S, Giorgio V, Gasbarrini A, Cammarota G. “Digestive Enzyme Supplementation in Gastrointestinal Diseases.” Curr Drug Metab. (2016);17(2):187-93.